4.5 Article

Unravelling the Immunotoxicity of Polycaprolactone Nanoparticles-Effects of Polymer Molecular Weight, Hydrolysis, and Blends

期刊

CHEMICAL RESEARCH IN TOXICOLOGY
卷 33, 期 11, 页码 2819-2833

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.chemrestox.0c00208

关键词

-

资金

  1. European Regional Development Fund (ERDF), through the Centro 2020 Regional Operational Programme
  2. European Regional Development Fund (ERDF) through the COMPETE 2020-Operational Programme for Competitiveness and Internationalization
  3. Portuguese national funds via FCT-Fundacao para a Ciencia e Tecnologia [PROSAFE/0001/2016, POCI-01-0145-FEDER-030331, POCI-01-0145-FEDER-032610-PTDC/MEC-DER/32610/2017, UIDB/04539/2020, UIDB/04326/2020, UIDB/04565/2020]
  4. Fundação para a Ciência e a Tecnologia [UIDB/04539/2020, UIDB/04326/2020, ProSafe/0001/2016, UIDB/04565/2020] Funding Source: FCT

向作者/读者索取更多资源

Poly-epsilon-caprolactone (PCL) is a biodegradable polyester that has FDA and CE approval as a medical device. Nonetheless, the lack of toxicity exhibited by the polymer cannot be extrapolated to its nanomaterial conformation. Despite PCL-based NPs being widely studied in the biomedical field for their advantages as controlled drug delivery systems, little data describe PCL NPs' toxicity, particularly immunotoxicity. This work assessed different PCL-based delivery systems intended for protein delivery regarding their immunotoxicity and hemocompatibility. Two different molecular weight PCL polymers were used, as well as blends with chitosan and glucan. Results showed that the presence of NaOH during the production of PCL2 NPs and PCL2/glucan NPs induced PCL alkali hydrolysis, generating more reactive groups (carboxyl and hydroxyl) that contributed to an increased toxicity of the NPs (higher reduction in peripheral blood mononuclear cell viability and lower hemocompatibility). PCL2/glucan NPs showed an anti-inflammatory activity characterized by the inhibition of LPS stimulated nitric oxide (NO) and TNF-alpha. In conclusion, generalizations among different PCL NP delivery systems must be avoided, and immunotoxicity assessments should be performed in the early stage of product development to increase the clinical success of the nanomedicine.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据